全文获取类型
收费全文 | 23301篇 |
免费 | 3009篇 |
国内免费 | 705篇 |
专业分类
耳鼻咽喉 | 162篇 |
儿科学 | 277篇 |
妇产科学 | 378篇 |
基础医学 | 4484篇 |
口腔科学 | 1228篇 |
临床医学 | 1801篇 |
内科学 | 4498篇 |
皮肤病学 | 481篇 |
神经病学 | 1863篇 |
特种医学 | 400篇 |
外国民族医学 | 2篇 |
外科学 | 2180篇 |
综合类 | 1848篇 |
现状与发展 | 8篇 |
预防医学 | 973篇 |
眼科学 | 830篇 |
药学 | 2950篇 |
7篇 | |
中国医学 | 1073篇 |
肿瘤学 | 1572篇 |
出版年
2024年 | 73篇 |
2023年 | 589篇 |
2022年 | 636篇 |
2021年 | 1509篇 |
2020年 | 1225篇 |
2019年 | 1209篇 |
2018年 | 1159篇 |
2017年 | 1194篇 |
2016年 | 1218篇 |
2015年 | 1345篇 |
2014年 | 1576篇 |
2013年 | 2646篇 |
2012年 | 1196篇 |
2011年 | 1322篇 |
2010年 | 1090篇 |
2009年 | 1100篇 |
2008年 | 1079篇 |
2007年 | 1048篇 |
2006年 | 940篇 |
2005年 | 746篇 |
2004年 | 673篇 |
2003年 | 529篇 |
2002年 | 471篇 |
2001年 | 373篇 |
2000年 | 273篇 |
1999年 | 252篇 |
1998年 | 238篇 |
1997年 | 183篇 |
1996年 | 172篇 |
1995年 | 146篇 |
1994年 | 118篇 |
1993年 | 127篇 |
1992年 | 81篇 |
1991年 | 64篇 |
1990年 | 48篇 |
1989年 | 44篇 |
1988年 | 42篇 |
1987年 | 38篇 |
1986年 | 25篇 |
1985年 | 36篇 |
1984年 | 40篇 |
1983年 | 33篇 |
1982年 | 21篇 |
1981年 | 26篇 |
1980年 | 18篇 |
1979年 | 13篇 |
1978年 | 10篇 |
1977年 | 7篇 |
1976年 | 7篇 |
1975年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 16 毫秒
1.
2.
3.
良性前列腺增生(BPH)是老年男性常见的泌尿系统疾病,其发病与前列腺慢性炎症之间存在显著相关。感染因子、尿液返流、代谢综合征、衰老过程和自身免疫应答在内的几种刺激,通过相应分子途径引起前列腺免疫细胞的组织定位和组成成分发生广泛改变,从而导致免疫系统失调,之后引发的组织损伤和缓慢愈合,导致了BPH发生和进展。本文通过总结良性前列腺增生与前列腺慢性炎症的相关性的临床研究结果,前列腺免疫细胞在病理生理机制层面与前两者之间的内在联系,以及抗炎药物对BPH-LUTS的干预作用,以其为BPH-LUTS的药物研发提供参考。 相似文献
4.
5.
目的 对学龄期近视进展儿童进行调节功能的客观检查与分析,观察调节功能与近视进展之间的相关性。方法 选取2017年至2018年在首都医科大学附属北京同仁医院视光学门诊定期就诊的71名学龄期儿童为研究对象,根据受试者近年的屈光度进展速度,按≤0.50 D·a-1、>0.50~1.00 D·a-1、>1.00~1.50 D·a-1、>1.50 D·a-1分为4组,使用人眼调节分析仪对受试者进行调节功能的客观测量与分析,记录不同调节刺激视标下4组的客观调节反应值和客观调节微波动值,并作对比。结果 在所有调节视标上,各组随着调节刺激幅度增加,客观调节反应值也逐渐增加,4组在不同调节刺激视标下的客观调节反应值及平均的客观调节反应值差异均无统计学意义(均为P>0.05)。≤0.50 D·a-1、>0.50~1.00 D·a-1、>1.00~1.50 D·a-1、>1.50 D·a-1近视进展速度组调节微波动值分别为(62.2±5.6)D、(62.5±5.3)D、(66.5±6.0)D和(58.0±6.5)D,4组间差异有统计学意义(F=6.424,P=0.001),在+0.50~-0.50 D、-2.00 D调节刺激视标下,4组的客观调节微波动值比较差异均有统计学意义(均为P<0.05),在其余调节刺激视标下差异均无统计学意义(均为P>0.05)。结论 对于学龄期儿童的近视进展速度,客观调节微波动值相对于客观调节反应值可能是一个更为敏感的相关指标。 相似文献
6.
《Journal of endodontics》2020,46(10):1455-1464
IntroductionThe aim of this study was to investigate whether mineral trioxide aggregate (MTA) can be modified with caffeic acid (CA) to form caffeic acid/mineral trioxide aggregate (CAMTA) cement and to evaluate its physicochemical and biological properties as well as its capability in immune suppression and angiogenesis.MethodsMTA was immersed in trishydroxymethyl aminomethane buffer with CA to allow coating onto MTA powders. X-ray diffractometry and tensile stress-strain tests were conducted to assess for physical characteristics of CAMTA and to evaluate for successful modification of MTA. Then, the CAMTA cement was immersed in simulated body fluid to evaluate its hydroxyapatite formation capabilities and Si release profiles. In addition, RAW 264.7 cells and human dental pulp stem cells were used to evaluate CAMTA’s immunosuppressive capabilities and cell responses, respectively. hDPSCs were also used to assess CAMTA’s angiogenic capabilities.ResultsThe X-ray diffractometry results showed that CA can be successfully coated onto MTA without disrupting or losing MTA’s original structural properties, thus allowing us to retain the initial advantages of MTA. CAMTA was shown to have higher mechanical properties compared with MTA and had rougher pitted surfaces, which were hypothesized to lead to enhanced adhesion, proliferation, and secretion of angiogenic- and odontogenic-related proteins. In addition, it was found that CAMTA was able to enhance hydroxyapatite formation and immunosuppressive capabilities compared with MTA.ConclusionsCAMTA cements were found to have improved physicochemical and biological characteristics compared with their counterpart. In addition, CAMTA cements had enhanced odontogenic, angiogenic, and immunosuppressive properties compared with MTA. All of the results of this study proved that CAMTA cements could be a biomaterial for future clinical applications and tissue engineering use. 相似文献
7.
8.
Ahmed M. Abu El-Asrar Ajmal Ahmad Eef Allegaert Mohammad Mairaj Siddiquei Priscilla W. Gikandi Gert De Hertogh 《Ocular immunology and inflammation》2020,28(4):575-588
ABSTRACT
Purpose
To investigate the expression of IL-11 and its receptor IL-11Rα and to quantify density of CD163+ M2 macrophages in proliferative diabetic retinopathy (PDR). 相似文献9.
支气管哮喘是由多种细胞和细胞组分参与的气道慢性炎症性疾病,其气道炎症反应的复杂性,给临床诊断和治疗带来了困难[1]。2009年全球哮喘防治倡议(GINA)第一次提出“表型”这一概念,并提出基于表型分类有助于哮喘治疗及判断预后[2]。中医药治疗哮喘有其独特优势,但辨证分型缺乏明确统一的客观化、量化指标。 相似文献
10.
《Journal of vascular and interventional radiology : JVIR》2020,31(1):25-34
PurposeTo investigate the safety of yttrium-90 radioembolization in combination with checkpoint inhibitor immunotherapy for the treatment of hepatocellular carcinoma (HCC).Materials and MethodsThis single-center retrospective study included 26 consecutive patients with HCC who received checkpoint inhibitor immunotherapy within 90 days of radioembolization from April 2015 to May 2018. Patients had preserved liver function (Child-Pugh scores A–B7) and either advanced HCC due to macrovascular invasion or limited extrahepatic disease (21 patients) or aggressive intermediate stage HCC that resulted in earlier incorporation of systemic immunotherapy (5 patients). Clinical documentation, laboratory results, and imaging results at 1- and 3-month follow-up intervals were reviewed to assess treatment-related adverse events and treatment responses.ResultsThe median follow-up period after radioembolization was 7.8 months (95% confidence interval [CI], 5.6–11.8). There were no early (30-day) mortality or grades 3/4 hepatobiliary or immunotherapy-related toxicities. Delayed grades 3/4 hepatobiliary toxicities (1–3 months) occurred in 2 patients in the setting of HCC disease progression. One patient developed pneumonitis. The median overall survival from first immunotherapy was 17.2 months (95% CI, 10.9–23.4). The median overall survival from first radioembolization was 16.5 months (95% CI, 6.6–26.4). From first radioembolization, time to tumor progression was 5.7 months (95% CI, 4.2–7.2), and progression-free survival was 5.7 months (95% CI, 4.3–7.1).ConclusionsRadioembolization combined with checkpoint inhibitor immunotherapy in cases of HCC appears to be safe and causes limited treatment-related toxicity. Future prospective studies are needed to identify the optimal combination treatment protocols and evaluate the efficacy of combination therapy. 相似文献